Eli Lilly's forforglipron Success Spurs Global Obesity and Diabetes Treatment Approvals
TL;DR Summary
Eli Lilly announced that its anti-obesity pill, orforglipron, successfully met weight-loss targets in a key diabetes trial, reducing body weight by 10.5% on average, which boosts its plans for FDA approval and intensifies competition with Novo Nordisk in the weight-loss drug market.
- Eli Lilly’s weight-loss pill meets target in key diabetes trial Financial Times
- Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval CNBC
- Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Eli Lilly and Company
- Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals The Wall Street Journal
- Eli Lilly's oral GLP-1 pill may help people with Type 2 diabetes lose 'significant' weight, study finds ABC News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
90%
435 → 42 words
Want the full story? Read the original article
Read on Financial Times